Medical - Instruments & Supplies
Compare Stocks
2 / 10Stock Comparison
COO vs JNJ
Revenue, margins, valuation, and 5-year total return — side by side.
Drug Manufacturers - General
COO vs JNJ — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ||
|---|---|---|
| Industry | Medical - Instruments & Supplies | Drug Manufacturers - General |
| Market Cap | $11.97B | $541.31B |
| Revenue (TTM) | $4.15B | $92.15B |
| Net Income (TTM) | $401M | $25.12B |
| Gross Margin | 64.2% | 68.1% |
| Operating Margin | 17.2% | 26.1% |
| Forward P/E | 13.2x | 19.4x |
| Total Debt | $2.78B | $36.63B |
| Cash & Equiv. | $111M | $24.11B |
COO vs JNJ — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| The Cooper Companie… (COO) | 100 | 77.1 | -22.9% |
| Johnson & Johnson (JNJ) | 100 | 151.0 | +51.0% |
Price return only. Dividends and distributions are not included.
Quick Verdict: COO vs JNJ
Each card shows where this stock fits in a portfolio — not just who wins on paper.
COO is the clearest fit if your priority is growth exposure and sleep-well-at-night.
- Rev growth 5.1%, EPS growth -4.6%, 3Y rev CAGR 7.3%
- Lower volatility, beta 0.93, Low D/E 33.8%, current ratio 1.89x
- 5.1% revenue growth vs JNJ's 4.3%
JNJ carries the broadest edge in this set and is the clearest fit for income & stability and long-term compounding.
- Dividend streak 36 yrs, beta 0.06, yield 2.2%
- 136.2% 10Y total return vs COO's 59.8%
- Beta 0.06, yield 2.2%, current ratio 1.11x
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 5.1% revenue growth vs JNJ's 4.3% | |
| Value | Lower P/E (13.2x vs 19.4x) | |
| Quality / Margins | 27.3% margin vs COO's 9.7% | |
| Stability / Safety | Beta 0.06 vs COO's 0.93 | |
| Dividends | 2.2% yield; 36-year raise streak; the other pay no meaningful dividend | |
| Momentum (1Y) | +48.8% vs COO's -24.1% | |
| Efficiency (ROA) | 13.0% ROA vs COO's 3.2%, ROIC 20.7% vs 4.8% |
COO vs JNJ — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
COO vs JNJ — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
Income & Cash Flow (Last 12 Months)
JNJ leads this category, winning 6 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
JNJ is the larger business by revenue, generating $92.1B annually — 22.2x COO's $4.2B. JNJ is the more profitable business, keeping 27.3% of every revenue dollar as net income compared to COO's 9.7%.
| Metric | ||
|---|---|---|
| RevenueTrailing 12 months | $4.2B | $92.1B |
| EBITDAEarnings before interest/tax | $1.0B | $31.4B |
| Net IncomeAfter-tax profit | $401M | $25.1B |
| Free Cash FlowCash after capex | $333M | $19.1B |
| Gross MarginGross profit ÷ Revenue | +64.2% | +68.1% |
| Operating MarginEBIT ÷ Revenue | +17.2% | +26.1% |
| Net MarginNet income ÷ Revenue | +9.7% | +27.3% |
| FCF MarginFCF ÷ Revenue | +8.0% | +20.7% |
| Rev. Growth (YoY)Latest quarter vs prior year | +6.2% | +6.8% |
| EPS Growth (YoY)Latest quarter vs prior year | +26.9% | +91.0% |
Valuation Metrics
COO leads this category, winning 5 of 6 comparable metrics.
Valuation Metrics
At 32.7x trailing earnings, COO trades at a 16% valuation discount to JNJ's 38.8x P/E. On an enterprise value basis, COO's 13.2x EV/EBITDA is more attractive than JNJ's 18.8x.
| Metric | ||
|---|---|---|
| Market CapShares × price | $12.0B | $541.3B |
| Enterprise ValueMkt cap + debt − cash | $14.6B | $553.8B |
| Trailing P/EPrice ÷ TTM EPS | 32.68x | 38.79x |
| Forward P/EPrice ÷ next-FY EPS est. | 13.24x | 19.39x |
| PEG RatioP/E ÷ EPS growth rate | — | 34.49x |
| EV / EBITDAEnterprise value multiple | 13.24x | 18.78x |
| Price / SalesMarket cap ÷ Revenue | 2.93x | 6.09x |
| Price / BookPrice ÷ Book value/share | 1.48x | 7.63x |
| Price / FCFMarket cap ÷ FCF | 27.61x | 27.28x |
Profitability & Efficiency
JNJ leads this category, winning 5 of 8 comparable metrics.
Profitability & Efficiency
JNJ delivers a 31.7% return on equity — every $100 of shareholder capital generates $32 in annual profit, vs $5 for COO. COO carries lower financial leverage with a 0.34x debt-to-equity ratio, signaling a more conservative balance sheet compared to JNJ's 0.51x.
| Metric | ||
|---|---|---|
| ROE (TTM)Return on equity | +4.8% | +31.7% |
| ROA (TTM)Return on assets | +3.2% | +13.0% |
| ROICReturn on invested capital | +4.8% | +20.7% |
| ROCEReturn on capital employed | +6.1% | +17.6% |
| Piotroski ScoreFundamental quality 0–9 | 5 | 5 |
| Debt / EquityFinancial leverage | 0.34x | 0.51x |
| Net DebtTotal debt minus cash | $2.7B | $12.5B |
| Cash & Equiv.Liquid assets | $111M | $24.1B |
| Total DebtShort + long-term debt | $2.8B | $36.6B |
| Interest CoverageEBIT ÷ Interest expense | 6.40x | 48.23x |
Total Returns (Dividends Reinvested)
JNJ leads this category, winning 6 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in JNJ five years ago would be worth $14,803 today (with dividends reinvested), compared to $6,033 for COO. Over the past 12 months, JNJ leads with a +48.8% total return vs COO's -24.1%. The 3-year compound annual growth rate (CAGR) favors JNJ at 13.9% vs COO's -14.1% — a key indicator of consistent wealth creation.
| Metric | ||
|---|---|---|
| YTD ReturnYear-to-date | -24.6% | +9.0% |
| 1-Year ReturnPast 12 months | -24.1% | +48.8% |
| 3-Year ReturnCumulative with dividends | -36.7% | +47.6% |
| 5-Year ReturnCumulative with dividends | -39.7% | +48.0% |
| 10-Year ReturnCumulative with dividends | +59.8% | +136.2% |
| CAGR (3Y)Annualised 3-year return | -14.1% | +13.9% |
Risk & Volatility
JNJ leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
JNJ is the less volatile stock with a 0.06 beta — it tends to amplify market swings less than COO's 0.93 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. JNJ currently trades 89.2% from its 52-week high vs COO's 68.0% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ||
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.93x | 0.06x |
| 52-Week HighHighest price in past year | $89.83 | $251.71 |
| 52-Week LowLowest price in past year | $60.00 | $146.12 |
| % of 52W HighCurrent price vs 52-week peak | +68.0% | +89.2% |
| RSI (14)Momentum oscillator 0–100 | 25.0 | 38.3 |
| Avg Volume (50D)Average daily shares traded | 2.0M | 7.0M |
Analyst Outlook
JNJ leads this category, winning 1 of 1 comparable metric.
Analyst Outlook
Wall Street rates COO as "Buy" and JNJ as "Buy". Consensus price targets imply 53.6% upside for COO (target: $94) vs 11.0% for JNJ (target: $249). JNJ is the only dividend payer here at 2.17% yield — a key consideration for income-focused portfolios.
| Metric | ||
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $93.86 | $249.27 |
| # AnalystsCovering analysts | 24 | 40 |
| Dividend YieldAnnual dividend ÷ price | — | +2.2% |
| Dividend StreakConsecutive years of raises | 0 | 36 |
| Dividend / ShareAnnual DPS | — | $4.87 |
| Buyback YieldShare repurchases ÷ mkt cap | +2.4% | +0.4% |
JNJ leads in 5 of 6 categories (Income & Cash Flow, Profitability & Efficiency). COO leads in 1 (Valuation Metrics).
COO vs JNJ: Frequently Asked Questions
10 questions · data-driven answers · updated daily
01Is COO or JNJ a better buy right now?
For growth investors, The Cooper Companies, Inc.
(COO) is the stronger pick with 5. 1% revenue growth year-over-year, versus 4. 3% for Johnson & Johnson (JNJ). The Cooper Companies, Inc. (COO) offers the better valuation at 32. 7x trailing P/E (13. 2x forward), making it the more compelling value choice. Analysts rate The Cooper Companies, Inc. (COO) a "Buy" — based on 24 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — COO or JNJ?
On trailing P/E, The Cooper Companies, Inc.
(COO) is the cheapest at 32. 7x versus Johnson & Johnson at 38. 8x. On forward P/E, The Cooper Companies, Inc. is actually cheaper at 13. 2x.
03Which is the better long-term investment — COO or JNJ?
Over the past 5 years, Johnson & Johnson (JNJ) delivered a total return of +48.
0%, compared to -39. 7% for The Cooper Companies, Inc. (COO). Over 10 years, the gap is even starker: JNJ returned +136. 2% versus COO's +59. 8%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — COO or JNJ?
By beta (market sensitivity over 5 years), Johnson & Johnson (JNJ) is the lower-risk stock at 0.
06β versus The Cooper Companies, Inc. 's 0. 93β — meaning COO is approximately 1534% more volatile than JNJ relative to the S&P 500. On balance sheet safety, The Cooper Companies, Inc. (COO) carries a lower debt/equity ratio of 34% versus 51% for Johnson & Johnson — giving it more financial flexibility in a downturn.
05Which is growing faster — COO or JNJ?
By revenue growth (latest reported year), The Cooper Companies, Inc.
(COO) is pulling ahead at 5. 1% versus 4. 3% for Johnson & Johnson (JNJ). On earnings-per-share growth, the picture is similar: The Cooper Companies, Inc. grew EPS -4. 6% year-over-year, compared to -57. 8% for Johnson & Johnson. Over a 3-year CAGR, COO leads at 7. 3% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — COO or JNJ?
Johnson & Johnson (JNJ) is the more profitable company, earning 15.
8% net margin versus 9. 2% for The Cooper Companies, Inc. — meaning it keeps 15. 8% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: JNJ leads at 24. 9% versus 16. 7% for COO. At the gross margin level — before operating expenses — JNJ leads at 69. 1%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is COO or JNJ more undervalued right now?
On forward earnings alone, The Cooper Companies, Inc.
(COO) trades at 13. 2x forward P/E versus 19. 4x for Johnson & Johnson — 6. 1x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for COO: 53. 6% to $93. 86.
08Which pays a better dividend — COO or JNJ?
In this comparison, JNJ (2.
2% yield) pays a dividend. COO does not pay a meaningful dividend and should not be held primarily for income.
09Is COO or JNJ better for a retirement portfolio?
For long-horizon retirement investors, Johnson & Johnson (JNJ) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.
06), 2. 2% yield, +136. 2% 10Y return). Both have compounded well over 10 years (JNJ: +136. 2%, COO: +59. 8%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between COO and JNJ?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
JNJ pays a dividend while COO does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.